Diabetes Mellitus (T1 vs T2) for USMLE Step 1 & Step 2 CK

Learn Type 1 vs Type 2 diabetes pathophysiology, classic presentations, DKA vs HHS differences, and mechanism-based therapy (metformin, insulin).

Introduction

Diabetes mellitus (DM) is a core USMLE Step 1 and USMLE Step 2 CK topic because it connects **endocrine pathophysiology** (insulin deficiency vs insulin resistance) to high-stakes clinical outcomes like **diabetic ketoacidosis (DKA)** and medication selection.

High-yield success comes from recognizing the *mechanism* behind hyperglycemia, predicting who is at risk for acute metabolic emergencies, and choosing therapies that match the underlying defect—especially **lifestyle therapy** and *metformin*.

Pathophysiology

Definition and unifying concept

**Diabetes mellitus** is a group of metabolic disorders defined by **chronic hyperglycemia** caused by defects in **insulin secretion**, **insulin action**, or both.

This single definition explains why the disease spans multiple phenotypes: some patients cannot make insulin (absolute deficiency), while others have insulin present but cannot use it effectively (insulin resistance).

Type 1 diabetes mellitus (T1DM): autoimmune β-cell failure

In **Type 1 DM**, the primary problem is **autoimmune destruction of pancreatic β-cells**, producing **absolute insulin deficiency**.

Step 1–style immunology associations are classic: **HLA-DR3/DR4** and autoantibodies including **islet cell antibodies** and **GAD antibodies**.

A key mechanistic consequence is that **C-peptide is low/absent** in T1DM, reflecting the loss of endogenous insulin production.

Type 2 diabetes mellitus (T2DM): insulin resistance with relative insulin deficiency

In **Type 2 DM**, the dominant defect is **peripheral insulin resistance** with **relative insulin deficiency**, often linked to **obesity** and the **metabolic syndrome**.

At a signaling level, T2DM involves **receptor-level and post-receptor insulin signaling defects**.

Because insulin is still produced (especially early), **C-peptide is normal or elevated**.

Why DKA happens in T1DM (and is less common in T2DM)

DKA represents the metabolic consequences of **absolute insulin deficiency**.

Without insulin, **hormone-sensitive lipase** activity increases, driving **lipolysis** and release of free fatty acids. These undergo hepatic **β-oxidation**, generating ketone bodies (**β-hydroxybutyrate** and **acetoacetate**) and producing a **high anion-gap metabolic acidosis**.

In T2DM, **residual insulin** typically suppresses ketogenesis, so DKA risk is **low**.

Hypoglycemia physiology: counter-regulation

Hypoglycemia (often from **exogenous insulin** or **insulin secretagogues**) triggers counter-regulatory hormones: **epinephrine, cortisol, growth hormone, and glucagon**.

**Glucagon** is the primary rapid responder, restoring glucose via **hepatic glycogenolysis**.

Mechanistically, glucagon signals through a **G\_s protein–coupled receptor**, activating pathways that stimulate **glycogen phosphorylase**.

If glucagon is ineffective, suspect **depleted glycogen stores**, such as with **prolonged fasting, alcoholism, or endurance exercise**.

Clinical Presentation

Type 1 DM: classic Step 2 CK vignette pattern

T1DM often presents with:

• **Polyuria**
• **Polydipsia**
• **Weight loss**
• Possible **DKA**

A typical clinical scenario is a **lean adolescent** with rapid symptom onset.

Type 2 DM: insulin resistance phenotype

T2DM typically presents in adults with:

• **Central obesity**
• **Acanthosis nigricans**
• Gradual onset of hyperglycemic symptoms

The slower onset reflects the presence of residual insulin and a more progressive decline in β-cell function over time.

Acute metabolic emergencies: DKA vs HHS

Two hyperglycemic crises represent opposite ends of insulin deficiency:

• **DKA**: absolute insulin deficiency (usually T1DM) → ketogenesis + high anion-gap metabolic acidosis
• **Hyperosmolar hyperglycemic state (HHS)**: relative insulin deficiency (usually T2DM) → extreme hyperglycemia and osmotic diuresis **without significant ketosis**

Diagnostic Approach

Classifying diabetes: mechanism-first thinking

For USMLE-style differentiation, anchor on mechanism:

• **T1DM**: autoimmune β-cell destruction → absolute insulin deficiency
• **T2DM**: insulin resistance ± β-cell exhaustion

Then use supportive features:

• Body habitus (lean vs obese/central adiposity)
• Onset (rapid vs gradual)
• **C-peptide** (low/absent vs normal/high)
• DKA risk (high vs low)

DKA vs HHS: key diagnostic parameters

The following features help distinguish DKA from HHS in clinical stems.

| Parameter | DKA | HHS | |:---|:---|:---| | Typical patients | Type 1 DM, younger | Type 2 DM, older | | Plasma glucose | 250–600 mg/dL | >600 mg/dL | | Ketones | Present (*β-hydroxybutyrate*, *acetoacetate*) | Minimal or absent | | Arterial pH | <7.3 | >7.3 | | Serum osmolality | Increased | Markedly increased | | Potassium status | Total body K⁺ depleted despite normal/high serum K⁺ | Total body K⁺ severely depleted |

Hypoglycemia: recognizing common etiologies and immediate treatment

Common etiologies include:

• **Insulin overdose**
• **Missed meals**
• **Renal failure**
• **Exercise**

Treatment depends on mental status:

• If awake: **oral glucose**
• If unconscious: **IV dextrose** or **IM glucagon**

Management & Prevention

Foundation for all diabetes: lifestyle therapy

**Lifestyle therapy** is foundational across diabetes types:

• Dietary modification
• Weight reduction
• Physical activity

This is high-yield because it is universally correct in management questions, regardless of whether the patient ultimately needs medications.

Mechanism-based pharmacology (USMLE Step 1 + Step 2 CK integration)

Pharmacologic therapy is tailored to:

• Disease mechanism
• Comorbidities
• Patient-specific factors (including cardiovascular risk and weight goals)

Metformin

*Metformin*:

• **Decreases hepatic gluconeogenesis**
• **Increases peripheral insulin sensitivity**
• Weight-neutral to modest weight loss
• Contraindicated in **severe renal or hepatic impairment**
• Proven cardiovascular benefit

Step 1 mechanism pearl: metformin activates **AMP-activated protein kinase (AMPK)** to suppress gluconeogenesis.

Sulfonylureas

*Sulfonylureas*:

• Close **ATP-sensitive K⁺ channels** on β-cells → depolarization → Ca²⁺ influx → **insulin release**
• Risks: **hypoglycemia** and **weight gain**

Step 1 molecular target pearl: action is at the β-cell K\_ATP channel via the **SUR1 subunit**.

GLP-1 receptor agonists

*GLP-1 receptor agonists*:

• Increase glucose-dependent insulin release
• Decrease glucagon
• Slow gastric emptying
• Promote satiety → weight loss
• Cardiovascular benefit

SGLT2 inhibitors

*SGLT2 inhibitors*:

• Block renal glucose reabsorption → glycosuria
• Mild blood pressure reduction
• Weight loss
• Reduce heart failure and CKD progression

Insulin

*Insulin*:

• Required in **T1DM**
• Used in advanced T2DM
• Anabolic; increases glucose uptake into muscle and adipose tissue
• May cause weight gain

Step 2 CK therapy reasoning (sequencing)

A common Step 2 CK approach:

1. Initiate **metformin** unless contraindicated.
2. Add a **GLP-1 receptor agonist** or **SGLT2 inhibitor** when weight loss or ASCVD/HF/CKD benefit is desired.
3. Start **basal–bolus insulin** for symptomatic hyperglycemia or markedly elevated A1c.

DKA treatment sequence (high-yield order)

For DKA, master the sequence:

1. **Aggressive IV fluids**
2. **IV insulin**
3. **Potassium replacement** as needed
4. Add **dextrose** when glucose ≈200–250 mg/dL so insulin can continue until the **anion gap closes**

In children, monitor for **cerebral edema**.

High-Yield Differentials & Pitfalls

Differentiating diabetes types and hyperglycemic crises

Use this table to avoid common exam traps (e.g., assuming all severe hyperglycemia is DKA, or assuming all ketosis implies T2DM cannot be involved).

| Condition | Key mechanism | Typical patient pattern | Key distinguishing features | Common pitfall | |:---|:---|:---|:---|:---| | **Type 1 DM** | Autoimmune β-cell destruction → **absolute insulin deficiency** | Lean, often youth; rapid onset | Islet cell + GAD antibodies; **HLA-DR3/DR4**; **C-peptide low/absent**; **high DKA risk** | Missing T1DM when the stem emphasizes dehydration and weight loss but doesn’t explicitly say “DKA” | | **Type 2 DM** | **Insulin resistance** ± β-cell exhaustion | Adult with central obesity; gradual onset | **Acanthosis nigricans**; **C-peptide normal/high**; DKA risk low (residual insulin suppresses ketogenesis) | Assuming normal/high C-peptide excludes diabetes; it supports T2DM mechanism | | **DKA** | Absolute insulin deficiency → lipolysis → ketogenesis → **anion-gap metabolic acidosis** | Usually T1DM, younger | Glucose 250–600 mg/dL; ketones present; pH <7.3; total body K⁺ depleted | Forgetting that serum K⁺ may be normal/high despite total body depletion | | **HHS** | Relative insulin deficiency → extreme hyperglycemia + osmotic diuresis without significant ketosis | Usually T2DM, older | Glucose >600 mg/dL; minimal/absent ketones; pH >7.3; markedly increased osmolality | Over-calling DKA just because the glucose is very high | | **Hypoglycemia from therapy** | Exogenous insulin or secretagogues → counter-regulatory response | Any treated patient | Counter-regulation via epinephrine, cortisol, GH, glucagon; treat with oral glucose vs IV dextrose/IM glucagon | Not linking ineffective glucagon response to depleted glycogen stores (fasting, alcoholism, endurance exercise) |

Exam Vignette

A 15-year-old with a lean body habitus presents with several days of polyuria, polydipsia, and weight loss. Labs show hyperglycemia and a high anion-gap metabolic acidosis with positive serum ketones.

• Lean adolescent + rapid onset symptoms points toward **Type 1 DM** (autoimmune β-cell destruction → absolute insulin deficiency).
• **Ketones** and **anion-gap metabolic acidosis** identify **DKA**, which is strongly associated with T1DM due to absolute insulin deficiency.
• Mechanism link: insulin deficiency increases hormone-sensitive lipase activity → free fatty acids → hepatic β-oxidation → ketone bodies.
• Treatment order is the tested pearl: **IV fluids → IV insulin → potassium replacement → add dextrose when glucose ~200–250 mg/dL** to continue insulin until the anion gap closes.

Key Takeaways

• **T1DM** is autoimmune (HLA-DR3/DR4; islet cell and GAD antibodies) with **low/absent C-peptide** and **high DKA risk**.
• **T2DM** is driven by **insulin resistance** with **normal/high C-peptide**, often in central obesity with **acanthosis nigricans**.
• **DKA** = absolute insulin deficiency → ketogenesis → **high anion-gap metabolic acidosis**; **HHS** = relative insulin deficiency → extreme hyperglycemia with minimal ketosis.
• *Metformin* targets the core defect in T2DM by decreasing hepatic gluconeogenesis and increasing insulin sensitivity; lifestyle therapy remains foundational for all.
• Hypoglycemia triggers counter-regulation (glucagon, epinephrine, cortisol, GH); treat based on consciousness (oral glucose vs IV dextrose/IM glucagon).

Keep Learning

If you can consistently map each vignette to the underlying defect—**autoimmune β-cell failure vs insulin resistance**—you’ll be able to predict complications (DKA vs HHS) and choose mechanism-based therapy on USMLE Step 1 and USMLE Step 2 CK; keep reinforcing these links as you work through endocrine core concepts at /core-concepts.